01—Abstract
Summary
Summary of the 10-Q filed August 7, 2025. Cited figures are marked; the original filing is the authoritative source.
Viatris Inc. reported a sharply weaker first half of 2025, driven mainly by a non-cash goodwill impairment.
For the six months ended June 30, 2025, total revenues were $6.84 billiona versus $7.46 billion a year earlier, and the company recorded a net loss of $3.05 billion, compared with a net loss of $212.5 million in the prior-year period. The loss was primarily due to a $2.94 billion goodwill impairment charge recorded in the first quarter after a triggering event tied to a sharp share price decline and higher geopolitical and economic uncertainty. Diluted loss per share was $2.58 for the six months.
In the second quarter alone, Viatris reported net loss of $4.6 millionb and earnings from operations of $233.0 million, compared with a net loss of $326.4 million and an operating loss of $239.9 million in the prior-year quarter. Operating trends were mixed. Net sales fell to $3.57 billion in the quarter from $3.79 billion, reflecting divestitures closed in 2024 and an estimated $160 million negative revenue impact from the FDA warning letter and import alert at the Indore, India facility.
Management estimates the Indore impact on 2025 total revenues at approximately $500 millionc and on earnings from operations at approximately $385 million. Adjusted EBITDA was $2.00 billion for the six months versus $2.40 billion a year earlier. Net cash provided by operating activities was $755.2 million, down from $993.7 million.
Long-term debt declined to $12.79 billiond from $14.04 billion, and the company repurchased about $350.4 million of stock in the first half. The filing also flags ongoing legal and tax exposures, including an accrual of approximately $335 million related to a proposed opioid settlement framework of up to $335 million, a $284.0 million fair value loss on the Biocon Biologics CCPS in the quarter, and a pending FDA-related import alert. The company declared a quarterly dividend of $0.12 per share on August 4, 2025.
02—Key points
Key Highlights
- Six-month net loss of $3.05 billion, including a $2.94 billion goodwill impairment charge recorded in Q1 2025 (versus a $212.5 million net loss in the prior-year period).
- Second-quarter net loss narrowed to $4.6 million from $326.4 million a year earlier, with earnings from operations of $233.0 million versus an operating loss of $239.9 million.
- Total revenues were $3.58 billion in Q2 2025 (down 6% from $3.80 billion) and $6.84 billion for the six months (down from $7.46 billion); net sales decline partly reflects divestitures and the Indore Impact.
- FDA warning letter and import alert at the Indore, India facility: estimated 2025 total revenue impact of approximately $500 million and earnings from operations impact of approximately $385 million.
- Adjusted EBITDA was $2.00 billion for the six months ended June 30, 2025, compared with $2.40 billion a year earlier; net cash from operations was $755.2 million versus $993.7 million.
- Long-term debt decreased to $12.79 billion from $14.04 billion at year-end 2024, and the company had $566.4 million of cash and cash equivalents at June 30, 2025.
- Shareholder returns continued: $350.4 million of share repurchases and $283.1 million of cash dividends paid in the six months, with a $0.12 quarterly dividend declared August 4, 2025.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q2 FY2025, Viatris lost $0.00.
- Revenue$3.57B100.0%
- Cost of revenue−$2.24B62.7%
- Gross profit$1.33B37.3%
- Operating costs−$1.10B30.8%
- Operating income$233.0M6.5%
- Interest, other & tax−$237.6M6.7%
- Net income−$4.6M0.1%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 7, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $3.57B$3.79B | −5.7% |
| Cost of Revenue | $2.25B$2.35B | −4.3% |
| Gross Profit | $1.33B$1.45B | −7.8% |
| R&D Expenses | $218.80M$204.10M | +7.2% |
| SG&A Expenses | $928.70M$1.04B | −10.4% |
| Operating Expenses | $1.10B$1.69B | −34.7% |
| Operating Income | $233.00M-$239.90M | +197.1% |
| Interest Expense | $116.60M$145.80M | −20.0% |
| Net Income | -$4.60M-$326.40M | +98.6% |
| Shares Outstanding (Basic) | 1.17B1.19B | −1.5% |
| Shares Outstanding (Diluted) | 1.17B1.19B | −1.5% |
05—Questions
Frequently Asked Questions
Why did Viatris report such a large loss for the first half of 2025?
The loss was driven primarily by a $2.94 billion non-cash goodwill impairment charge recorded in the first quarter of 2025, after a triggering event tied to a sharp decline in the share price and higher geopolitical and economic uncertainty. The company also recorded a $399.8 million loss for the six months from remeasuring its Biocon Biologics CCPS to fair value.
Is the business performing better in the second quarter?
On an operating basis, the second quarter was better than the prior year: earnings from operations were $233.0 million versus an operating loss of $239.9 million, and net loss narrowed to $4.6 million from $326.4 million. However, total revenues fell 6% to $3.58 billion, reflecting divestitures and the Indore Impact.
What is the impact of the Indore manufacturing facility issues?
Following an FDA inspection in 2024, the FDA issued a warning letter and import alert affecting 11 actively distributed products that cannot be accepted into the U.S. until the warning letter is lifted. The company estimates the negative impact on 2025 total revenues at approximately $500 million and on earnings from operations at approximately $385 million, and says it has submitted responses within required time periods.
How is the company managing its debt and capital returns?
Long-term debt fell to $12.79 billion from $14.04 billion, and a $1.67 billion 2026 Senior Notes balance is now classified as current. The company had no borrowings outstanding under its $3.5 billion revolving facility, Commercial Paper Program, or $600 million Receivables Facility at June 30, 2025, and states it is in compliance with its covenants. It repurchased $350.4 million of stock in the first half and paid $283.1 million in dividends.
06—Continue